Abstract
Mycoplasma pneumoniae (M. pn) is one of the main pathogens causing community-acquired pneumonia (CAP) in children. In Japan, macrolide (ML)-resistant M. pn was firstly isolated from clinical samples collected from pediatric patients with CAP in 2000, and the agents have rapidly increased. All ML-resistant strains had a point mutation in domain V of the 23S rRNA. Among the patients with ML-resistant M. pn, the duration of fever was significantly longer than in patients with ML-susceptible M. pn infection. The antimicrobial agent was often changed from ML as a first choice agent to minocycline or levofloxacin, because of unimproved clinical symptoms. Further clinical studies are needed to establish appropriate chemotherapy.
| Original language | English |
|---|---|
| Pages (from-to) | 251-255 |
| Number of pages | 5 |
| Journal | Nihon rinsho. Japanese journal of clinical medicine |
| Volume | 70 |
| Issue number | 2 |
| Publication status | Published - 2012 Feb |
| Externally published | Yes |
Fingerprint
ASJC Scopus subject areas
- Medicine(all)
Cite this
[Macrolide-resistant Mycoplasma pneumoniae]. / Morozumi, Miyuki; Ubukata, Kimiko.
In: Nihon rinsho. Japanese journal of clinical medicine, Vol. 70, No. 2, 02.2012, p. 251-255.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - [Macrolide-resistant Mycoplasma pneumoniae].
AU - Morozumi, Miyuki
AU - Ubukata, Kimiko
PY - 2012/2
Y1 - 2012/2
N2 - Mycoplasma pneumoniae (M. pn) is one of the main pathogens causing community-acquired pneumonia (CAP) in children. In Japan, macrolide (ML)-resistant M. pn was firstly isolated from clinical samples collected from pediatric patients with CAP in 2000, and the agents have rapidly increased. All ML-resistant strains had a point mutation in domain V of the 23S rRNA. Among the patients with ML-resistant M. pn, the duration of fever was significantly longer than in patients with ML-susceptible M. pn infection. The antimicrobial agent was often changed from ML as a first choice agent to minocycline or levofloxacin, because of unimproved clinical symptoms. Further clinical studies are needed to establish appropriate chemotherapy.
AB - Mycoplasma pneumoniae (M. pn) is one of the main pathogens causing community-acquired pneumonia (CAP) in children. In Japan, macrolide (ML)-resistant M. pn was firstly isolated from clinical samples collected from pediatric patients with CAP in 2000, and the agents have rapidly increased. All ML-resistant strains had a point mutation in domain V of the 23S rRNA. Among the patients with ML-resistant M. pn, the duration of fever was significantly longer than in patients with ML-susceptible M. pn infection. The antimicrobial agent was often changed from ML as a first choice agent to minocycline or levofloxacin, because of unimproved clinical symptoms. Further clinical studies are needed to establish appropriate chemotherapy.
UR - http://www.scopus.com/inward/record.url?scp=84859973809&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84859973809&partnerID=8YFLogxK
M3 - Article
C2 - 22413527
AN - SCOPUS:84859973809
VL - 70
SP - 251
EP - 255
JO - Nihon rinsho. Japanese journal of clinical medicine
JF - Nihon rinsho. Japanese journal of clinical medicine
SN - 0047-1852
IS - 2
ER -